0.10Open0.25Pre Close40 Volume298 Open Interest15.00Strike Price440.00Turnover100.70%IV49.11%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.12Extrinsic Value100Contract SizeAmericanOptions Type0.1012Delta0.0635Gamma84.50Leverage Ratio-0.0091Theta0.0007Rho8.55Eff Leverage0.0049Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
No comment yet